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Abstract
Background: Lung cancer is the most common malignancies worldwide. However, the detailed molecular
mechanisms underlying lung cancer progression are still not completely clear. MicroRNAs are small noncoding
RNAs which occupy a crucial role of cancer metastasis. Accumulating evidence suggests that miR-361 plays
important roles in human carcinogenesis. However, its precise biological role remains largely elusive, especially in
lung cancer. This study examined the role of miR-361-3p in non-small cell lung cancer (NSCLC).
Methods: Real-time quantitative PCR (qRT-PCR) was used to analyze the expression of miR-361-3p in NSCLC tissue
and in compared adjacent non-cancerous tissues. The effect of miR-361-3p on proliferation was evaluated by CCK8
and colony formation assays. The effect of miR-361-3p on migration and invasion was evaluated by transwell assays.
Western blotting and immunohistochemical staining were applied to analyze the expression of target proteins and
downstream molecule, and the luciferase reporter assay to assess the target genes of miR-361-3p in non-small cell
lung cancer cells.
Results: miR-361-3p was significantly decreased in NSCLC tissue and cell lines, and its expression levels were highly
correlated with lymph node metastasis (P < 0.01) and TNM stages (P < 0.05). Down-regulation of miR-361-3p
promoted cell growth, proliferation, colony formation, invasion and migration in vitro, and promoted proliferation
and metastasis in vivo (P < 0.01); whereas up-regulation of miR-361-3p had the contrary effects. The luciferase
reporter assay showed that SH2B1 was a direct target gene of miR-361-3p. Enforced expression of miR-361-3p
inhibited the expression of SH2B1 significantly and the restoration of SH2B1 expression reversed the inhibitory
effects of miR-361-3p on NSCLC cell proliferation and metastasis.
Conclusions: miR-361-3p functions as a novel tumor suppressor in NSCLC and the anti-oncogenic activity may
involve its inhibition of the target gene SH2B1. These findings suggest the possibility for miR-361-3p as a
therapeutic target in NSCLC.
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Background
Lung cancer is the highest mortality malignant tumor in
China and African Americans [1, 2]. Non-small-cell lung
cancer (NSCLC) accounts for about 80 % of all lung can-
cer cases, including adenocarcinoma and squamous cell
carcinoma. Due to lacking obvious symptoms for early
diagnosis and highly malignant potential, the 5-year
survival rate of NSCLC is still less than 15 % [3]. Recent
years, low-dose computed tomography (LDCT) screen-
ing is employed in high risk patients to detect early stage
disease, while it was shown to reduce mortality its
usefulness is limited by high false-positive rates [4, 5].
These issues highlight the urgent need for accurate
that can detect early lung cancer with high sensitivity
and specificity.
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MicroRNAs (miRNAs) are highly conserved small
non-coding regulatory RNAs with sizes of 17–25 nucleo-
tides, which are able to regulate gene expression via
binding to the 3'-untranslated regions (UTR) of target
mRNAs [6], and was first reported by Ambros and Ruv-
kun in 1993 [7, 8]. Ample evidence shows that altered
miRNA expression result in the initiation, promotion,
and progression of NSCLC, such as miRNA-21 [9],
miRNA-205 [10], miR-1254 and miR-574-5p [11]. Al-
though the importance of miRNAs has attracted much
attention in recent years, the pathological relevance and
significance of the majority of miRNAs in NSCLC re-
main unclear. Thus, understanding of the underlying
molecular mechanisms of miRNA dysregulation in ma-
lignant tumors is critical to intervention of lung cancer.
Recent studies have shown that miR-361 expression
was alternant in several cancer types, for example squa-
mous cell carcinoma [12], cervical cancer [13], prostate
cancer [14], colorectal and gastric cancer [15], hepato-
cellular carcinoma [16]. Such researches imply that miR-
361 may play important roles in cancer depending on
the tumor type. In this study, we aimed to evaluate the
possible roles and related target genes of miR-361-3p in
tumorigenesis of NSCLC. We found that the expression
level of miR-361-3p in NSCLC was significantly lower in
NSCLC tissues than in the corresponding normal lung
tissues, and inversely associated with advanced stage
and lymph node metastasis of NSCLC. Furthermore,
enforced miR-361-3p expression inhibited lung cancer
cell growth, proliferation, clone formation, migration
and invasion in vitro, and tumorigenicity and intra-
pulmonary metastasis in vivo. In addition, The SH2B1
was identified as a functional target of miR-361-3p.
Therefore, down-regulation of miR-361-3p suppresses
lung cancer progression and metastasis through regu-
lation of SH2B1.
Results
Expression of miR-361-3p is inversely associated with
clinicopathologic characteristics and prognosis of NSCLC
In previous research, we noticed that miR-361-3p was
lowexpressed in NSCLC [17]. To confirm, we evaluated
the expression of miR-361-3p in 91 pairs of frozen
NSCLC tissues and the corresponding normal lung tis-
sues which located 5 cm apart from tumor by quantita-
tive reverse transcriptase PCR (qRT-PCR). For training
cohort, miR-361-3p expression was downregulated in
NSCLC tissues compared with the matching normal
lung tissues, the median was 0.70vs.1 (Fig. 1a). Further-
more, miR-361-3p expression was significantly inversely
associated with metastasis and tumor nodes and Metas-
tasis(TNM) stages of the patients (Table 1, P < 0.05). In
addition, miR-361-3p expression was significantly lower
in NSCLC tissue which displayed lymph node metastasis
than did not (Fig. 1b) (P <0.05), and decreased statisti-
cally with increasing stage of NSCLC (P < 0.05) (Fig.1c).
Therefore, the low miR-361-3p expression was closely
related to the progression and metastasis of NSCLC. We
also evaluated miR-361-3p expression in six NSCLC cell
lines (A549, HTB-182, PC-9, NCI-H1299, LTEP-A-2,
SPC-A-1) and a normal human bronchial epithelial cell
line (HBE). The relative expression levels for miR-361-
3p in these six NSCLC cell lines were 0.005, 0.091,
0.093, 0.118, 0.436, and 0.475, respectively, as compared
with that of HBE cells, respectively (Fig. 1d). Remark-
ably, A549 a squamous cell carcinoma cell line, and
HTB-182 an adenocarcinoma cell line, which expressed
the lowest miR-361-3p level, consistent with the associ-
ation of miR-361-3p with NSCLC metastasis as observed
in NSCLC patient samples.
MiR-361-3p inhibits NSCLC cell proliferation, migration
and invasion in vitro
To functionally characterize miR-361-3p in NSCLC, we
restored the expression of miR-361-3p by ectopic ex-
pression of this miRNA in the lowest expression NSCLC
cell line (A549 and HTB-182) and downregulated miR-
361-3p in the highest expression NSCLC cell line (SPC-
A-1). To this end miR-361-3p stably overexpressed
A549 miR-361-precursor and HTB-182 miR-361-precursor cells
and stably downregulated in SPCA-1anti-miR-361-3p cells
were generated. The different levels of miR-361-3p ex-
pression were confirmed by real-time PCR (Fig. 1e).
Cell Counting Kit-8(CCK8) and colony formation as-
says performed to assess the role of miR-361-3p in
NSCLC cell proliferation. The result showed that
compared with the control group, with forced expres-
sion of miR-361-3p impaired in both A549 miR-361-precursor
and HTB-182 miR-361-precursor cells, Cell Counting
Kit-8(CCK8) (Fig. 2a) and colony formation assays
(Fig. 2b) showed that cell proliferation were signifi-
cantly repressed. On the contrary, the cell proliferation of
SPCA-1anti-miR-361-3p cells was significantly enhanced.
Similarly, wound healing assay showed wound closure of
miR-361-3p impaired in both A549 miR-361-precursor and
HTB-182 miR-361-precursor were significantly slow. Further-
more, transwell assays showed the migratory and invasive
abilities was significantly decreased (Fig. 3a, b), whereas
reduced miR-361-3p expression inSPC-A-1anti-miR-361-3p
cells resulted in the opposite result (Fig. 3c). These results
indicated that miR-361-3p inhibits NSCLC cell prolifera-
tion and metastasis in vitro.
Overexpression of miR-361-3p inhibits tumor growth and
metastasis of NSCLC cells in vivo
Given that miR-361-3p impaired the proliferation, mi-
gration and invasion of NSCLC cells in vitro, we exam-
ined whether miR-361-3p could affect tumorigenicity
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and metastasis in vivo. A549 and HTB-182 cells stably
expressing miR-361-3p and negative control vector were
injected subcutaneously into nude mice. Palpable tumors
formed within 1 week. Tumor volume was measured
each week, and mice were sacrificed 4 weeks after tumor
cell implantation. The size of NSCLC tumors in these
two groups was calculated and compared. The average
tumor volume of A549 cells stably transfected with miR-
361-precursor was significantly smaller than tumors in
the negative control group (Fig. 4a). The tumor growth-
curve of tumor volume was drawn according to time
and a significant difference was shown between the two
groups (Fig. 4c). To investigate the in vivo role for miR-
361-3p in NSCLC cell migration, we examined the mice
Fig. 1 Low expression of miR-361-3p is inversely associated with TNM Classification and lymph node metastasis of NSCLC. a The expression of
miR-361-3p in 91 pairs of NSCLC tissues was significantly lower. b Low-level expression of miR-361-3p was associated with lymph node metastasis
of NSCLC, c TNM Classification of NSCLC. d miR-361-3p expression in NSCLC cell lines and HBE. e The level of miR-361-3p was significantly
changed in NSCLC cells after infected with miR-361-3p lentivirus or anti-miR-361-3p. Data were represented as the mean ± SEM of three
indepedent experiments. **P <0.01
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for lung metastasis of the A549 cells. As shown in Fig. 4,
Immunohistochemistry confirmed that the expression of
SH2B1 was significantly lower in A549miR-361-precursor
group than negative control groups (Fig. 4d). The intra-
pulmonary metastasis rate of A549 vector was 80 %,
whereas no metastasis was found in A549 miR-361-precursor
group (Fig. 4b, d). Together, these data support an im-
portant role formiR-361-3p in suppression of NSCLC
growth and metastasis in vivo.
SH2B1 is a direct downstream target of miR-361-3p
To explore the molecular mechanisms through which
miR-361-3p regulates NSCLC cell proliferation and
metastasis, we searched candidate target genes of miR-
361-3p using publicly available databases. Among the
candidates, SH2B1 exhibited one of the highest predic-
tion scores and the most complementary structure with
miR-361-3p (Fig. 5a). Moreover up-regulation of SH2B1
protein was found in various types cancer and high
SH2B1 expression is associated with more aggressive
phenotypes [18–20]. We then carried out a luciferase-
based assay to validate whether these genes were indeed
regulated by miR-361-3p. Luciferase vectors containing
the 3’-UTR of each gene were created and transfected
along with or without the miR-361-3p expressing plas-
mid into cells. Measurement of luciferase activity re-
vealed that miR-361-3p expression was associated with
marked reduction of the activity of SH2B1 UTR. The
specificity of this inhibition was demonstrated by the
finding that the activity of a mutant SH2B1 3’-UTR with
the putative binding site mutated was not affected by
miR-361-3p (Fig. 5b). In addition, western blot analysis
showed that SH2B1 protein expression was clearly de-
creased in A549 cells and HTB-182 cells transfected
with LV-miR-361-precursor, and increased in SPC-A-1
cells transfected with LV-anti-miR-361-3p (Fig. 5c). Fur-
thermore, to explore the relationship between miR-361-
3p and SH2B1 in clinical specimens, we examined
SH2B1 expression using immunohistochemical analysis
on FFPEs of 91 NSCLC specimens. SH2B1 expression
was positively correlated with TNM stage and lymph
node metastasis of NSCLC (P < 0.001) (Table 2). We
compared SH2B1 expression data from immunohisto-
chemistry analysis with results of miR-361-3p expression
level from qRT-PCR analysis on specimens of these
NSCLC tissues. There was an inverse correlation be-
tween miR-361-3p and SH2B1 expressions in these spec-
imens (Fig. 5d, e, R = −0.622, P < 0.001). Taken together,
these results indicated that SH2B1 was a direct down-
stream target for miR-361-3p in NSCLC cells.
Gain- and loss-of-function of SH2B1 abrogated or
mimicked impact of miR-361-3p on cell proliferation
and metastasis
To determine whether miR-361-3p-dependent inhibition
of NSCLC cell proliferation and metastasis was indeed
mediated by SH2B1, we used a complementary approach
of gain- and loss-of-function of SH2B1. Specifically we
transfected with si-SH2B1 to down the expression of
SH2B1, and transfected with a SH2B1 expression vector
to restore SH2B1 expression. The restoration of SH2B1
expression enhanced the proliferation (Fig. 6a) and col-
ony formation (Fig. 6b) of A549miR-361-precursor and HTB-
182 miR-361-precursorcells. Moreover, the restoration of
SH2B1 significantly attenuated miR-361-3p-mediated in-
hibition of A549miR-361-precursor and HTB-182 miR-361-precursor
cells migration and invasion (Fig. 7a, b). In contrast,
Table 1 miR-361-3p expression and clinicopathological features
in non-small cell lung cancer (NSCLC) patients
Variables n miR-361-3p expression
High expression Low expression p value*
Gender
Male 67 27(40 %) 40(60 %)
Female 24 6(25 %) 18(75 %) 0.181
Age(years)
> 55 56 20(36 %) 36(64 %)
≦55 35 13(37 %) 22(63 %) 0.890
Smoking history
Yes 54 20(37 %) 34(63 %)
No 37 13(35 %) 24(65 %) 0.853
Pathological type
Adenocarcinoma 54 18(34 %) 36(66 %)
Squamous
carcinoma
37 15(41 %) 22(59 %) 0.482
Tumor differentiation
High 22 10(45 %) 22(55 %)
Middle 58 21(36 %) 37(64 %)
Low 11 2(18 %) 9(82 %) 0.307
Tumor location
Right lung 45 17(38 %) 28(62 %)
Left lung 46 16(35 %) 30(65 %) 0.766
Tumor size(cm)
> 3 54 17(31 %) 27(69 %)
≦3 37 16(43 %) 21(57 %) 0.252
Lymphatic metastasis
Yes 42 8(19 %) 34(81 %)
No 49 23(47 %) 26(53 %) 0.002
TNM classification
I 43 22(51 %) 21(49 %)
II 22 6(27 %) 16(73 %)
III + IV 26 5(19 %) 21(81 %) 0.017
Abbreviations: TNM tumor-node-metastasis
* χ2test
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siSH2B1-mediated inhibition of SH2B1 expression
mimicked the effect of miR-361-3p on proliferation and
colony formation capacity in SPC-A-1 cellanti-miR-361-3p
(Figs. 6a, b and 7c).
We further investigated the role of SH2B1 in NSCLC
progression. The results showed that SH2B1 overexpres-
sion significantly promoted wound healing of SPC-A-
1cells (Fig. 7a). Downregulation of SH2B1 on the other
Fig. 2 miR-361-3p inhibited NSCLC cells proliferation in vitro. a miR-361-3p inhibited NSCLC cells proliferation determined using CCK8 assays.
b miR-361-3p inhibited NSCLC cells proliferation determined using colony formation. Data were represented as the mean ± SEM of three
independent experiments. *P < 0.05, **P < 0.01
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Fig. 3 (See legend on next page.)
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hand inhibited the proliferation (Fig. 6a), cell migration
and invasion of A549 (Fig. 7a) and HTB-182 cells
(Fig. 7b). These results together support an oncogenic
role of SH2B1 in NSCLC.
To explore whether miR-361-3p exerts its functions
through the JAK2-SH2B1-Rac1 pathways that contribute
to cancer proliferation, development and progression
[20], we examined a number of the main SH2B1 signal-
ing downstream target genes, including phosphorylation
of Janus kinases 2(p-JAK2), phosphorylation of Rho
GTPase Ras-related C3 botulinum toxin substrate 1(p-
Rac1), cAMP-Protein Kinase Catalytic subunit (PKA),
matrix metalloproteinase-2(MMP2), and MMP9. Over-
expression of p-JAK2, PKA, MMP2 and MMP9 and
downexpression of p-Rac1 were detected in A549 and
HTB-182 cells that stably overexpressed miR-361-3p
(Fig. 7d, lane 1–2). In contrast, downexpression of
p-JAK2, PKA, MMP2 and MMP9 and overexpression
of p-Rac1 were detected in SPC-A-1 cells with stable
down-regulation of miR-361-3p SH2B1 exhibited
lower SH2B1 expression (Fig. 7d, lane 3). These data
indicate that miR-361-3p inhibits SH2B1 signaling in
NSCLC, which involved tumor development and
progression.
Discussion
NSCLC is the most prevalent cancer types and has
highest mortality rate in China [1]; however, the pro-
gression mechanisms of NSCLC have largely remained
elusive. Ample evidence indicates a crucial role for
miRNAs in human cancer [21], especially the miR-
NAs participate in the initiation, promotion, and pro-
gression of NSCLC. For instance, miR-21 promotes
growth and invasion of NSCLC [22]. In addition,
miR-494, miR-101, miR-1254, miR-574-5p, miR-143
and miR-181a were demonstrated to be involved in
NSCLC [23–25]. In the present study, we certified
that miR-361-3p was frequently down-regulated in
NSCLC, and first found that the reduced miR-361-3p
expression was closely related to advanced stage and
lymph node metastasis of NSCLC. Furthermore, we
demonstrated that overexpression of miR-361-3p could
suppress NSCLC cell proliferation, migration and invasion
in vitro and in vivo. The versatile functions of miR-361-3p
in tumor cell proliferation, migration and invasion suggest
its potential application as a prognostic predictor and can-
cer therapeutic target.
SH2B1, which is an Src homology 2 (SH2) and pleck-
strin homology (PH) domain-containing protein, is
known an adapter protein, and can bind the large num-
ber of kinases, such as Janus kinase (JAK)-2 and JAK1
[26]; fibroblast growth factor receptor-1 [27]; insulin re-
ceptor [28]; insulin receptor substrate-1 [29]. It was re-
ported that SH2-Bβ functions as an adapter/scaffolding
protein that recruits Rac and perhaps other proteins to
activated membrane receptor-JAK complexes or recep-
tor tyrosine kinases where they are then positioned
appropriately to regulate the actin cytoskeleton and pro-
mote membrane ruffling and cell motility [20]. In our
study, we demonstrated that miR-361-3p can bind to a
sequence within the 3’-UTR of SH2B1 by luciferase-
based reporter assay. MiR-361-3p-mediated control of
SH2B1 expression was further validated by complemen-
tary gain- and loss-of-function approaches. Importantly,
ectopic SH2B1 expression could effectively impede the
ability of miR-361-3p to inhibit proliferation and metas-
tasis. Moreover, knockdown expression of SH2B1 abro-
gated the effects induced by miR-361-3p-inhibitor. Our
study provides solid evidence to support that miR-361-
3p inhibit proliferation and metastasis of NSCLC by dir-
ectly targeting SH2B1. For further study, we examined
the expression of SH2B1 signaling downstream target
genes and found that expression of p-JAK2, PKA,
MMP2 and MMP9 were decreased and p-Rac1 was
increased in NSCLC cells that stably overexpressed
miR-361-3p. In contrast, expression of p-JAK2, PKA,
MMP2 and MMP9 was significantly up-regulated and
p-Rac1was down-regulated in NSCLC cells that stably
expressed miR-361-3p inhibitor. This suggests that
SH2B1 activation resulted in increasing migration and
invasion is likely through activation of JAK2/Rac1
that regulates cell morphology and mobility as well as
membrane trafficking. Rac1 is a member of the Rho
family of small GTPases and participates in numerous
pathways inducing cytoskeleton reorganization, gene
transcription, cell proliferation and survival [30, 31],
especially in lung cancer modifies lung cancer migra-
tion, invasion and actin cytoskeleton rearrangements
and enhances chemosensitivity to antitumor drugs
[32, 33]. Schwarz J et al. reported that phosphoryl-
ation of Rac1 at serine-71 affects Rac1 activity by
shift specificity of GTPase/effector coupling and
modulates downstream signaling [34]. Thus, down-
regulation of p-Rac1 through inhibition of SH2B1
(See figure on previous page.)
Fig. 3 miR-361-3p inhibited NSCLC migration and invasion in vitro. a up-regulated miR-361-3p suppressed migration and invasion in vitro in
A549. b up-regulated miR-361-3p suppressed migration and invasion in vitro in HTB-182. c down-regulated miR-361-3p enhanced migration and
invasion in vitro in SPC-A-1 compared with controls. Data which were put beside picture c were represented as the mean ± SEM of three
independent experiments. *P < 0.05, **P < 0.01
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Fig 4 Overexpression of miR-361-3p inhibits NSCLC in vivo. a The NSCLC mouse subcutaneous implantation model in mice was constructed by
using A549&HTB-182 cells infected with negative control and miR-361-precursor. Tumor volumes of subcutaneous implantation models of A549
are shown; and tumor volumes in the orthotopic implantation models at week 3or4 are shown. b Tumor volumes of intravenous metastasis
models of A549 are shown. c Tumor growth curves of subcutaneous implantation models of NSCLC. d The expression of SH2B1 in local tumor
tissues was determined by immunohistochemistry. e The percentage of mice with or without metastatic nodules in the lungs was calculated and
compared. Data were represented as the mean ± SEM of three independent experiments. **P < 0.01
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could be a mechanism by which miR-361-3p sup-
presses cell proliferation, migration and invasion.
MMPs are a family of enzymes that proteolytically de-
grade various components of the extracellular matrix
[35]. High levels of certain MMPs are closely corre-
lated with the invasive and metastatic potential of tu-
mors [36, 37]. Specifically, activated Rac1 regulates
tumor invasion of lung cancer cells by regulating gene
transcription of MMP2 and MMP9 [38]. These data
indicate that miR-361-3p suppresses progression of
NSCLC through inhibition of the versatile tumor-
promoting SH2B1. It is noteworthy that neither miR-
361-3p nor SH2B1 has been investigated in NSCLC.
Our report revealed a novel miR-361-SH2B1 axis in
regulation of NSCLC.
SH2B1 is identified as a target of miR-361-3p, but
SH2B1 might not solely be explained the antioncogenic
properties of miR-361-3p, because a single miRNA can
potentially regulate dozens to hundreds of genes in
tumorigenesis [39]. Therefore, future studies to identify
additional novel targets of miR-361-3p and other miR-
NAs that can also regulate SH2B1 will allow us to have
deep understanding of the mechanisms underlying the
development and progression of NSCLC.
In conclusion, our results show that miR-361-3p is sig-
nificantly downregulated in NSCLC. This miRNA can
Fig. 5 SH2B1 is a direct downstream target of miR-361-3p. a Schematic of the construction of wild-type or mutant SH2B1 3'-UTR vectors is
illustrated. b Relative luciferase activity was analyzed in A549 and HTB-182 cells. Firefly luciferase vector was used as an internal control. c Western
blot results of SH2B1 protein in A549, HTB-182 and SPC-A-1 cells infected with miR-361-precursor lentivirus or anti-miR-361-p. d The representative
IHC pictures showed the SH2B1 protein expression in NSCLC tissue with high or low miR-361-3p expression. e The inverse correlation between
the expression of miR-361-3p and SH2B1 in the same set of NSCLC tissue specimens. Data were represented as the mean ± SEM of three
independent experiments. **P < 0.01
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potently inhibit NSCLC cell proliferation and metastasis
in vitro and in vivo. The tumor-suppressive role of miR-
361-3p is largely mediated by one of its target, Sh2B1.
These findings provide new insight into the molecular
pathogenesis of NSCLC and implicate miR-361-3p as a
potential prognostic biomarker and therapeutic target of
NSCLC.
Conclusions
Carcinogenesis is a series of sequential events, including
growth, proliferation, migration, and local invasion.
Herein, we showed that miR-361-3p could suppress the
carcinogenesis of NSCLC through inhibition of growth,
proliferation, migration and invasion. Furthermore, our
evidence suggests that miR-361-3p is a potential thera-
peutic target in NSCLC. Further studies are required to
fully understand the detailed mechanisms of miR-361-3p




Written informed consent was obtained from all partici-
pants, and the study protocol was approved by the ethics
committee of Xiangtan Hospital, Central South Univer-
sity (CSU). All mouse experiments were approved by the
Animal Care and Use Committee and conducted in ac-
cordance with the official recommendations of the Care
and Use Laboratory Animals of Xiangtan Hospital, CSU.
Patient and tissue samples
Primary cancer tissues and paired adjacent non-tumor
tissues were collected from 91 patients with NSCLC
underwent lung resection at the Department of Surgery,
Xiangtan Hospital of Central South University from
March 2013 to June 2014. Patients did not receive any
preoperative cancer treatments, such as radiotherapy or
chemotherapy. Each specimen was rapidly frozen in li-
quid nitrogen, and transferred to the −80 °C refrigerator
for subsequent experiments. The collected samples were
confirmed by an experienced pathologist. The clinical
data of NSCLC patients including tumor-node metasta-
sis (TNM) staging were also collected.
Cell lines and cell culture
Six NSCLC cell lines (HTB-182, A549, SPC-A-1, H1299,
PC-9, LTEP-A-2) were obtained from the American
Type Culture Collection. A normal human bronchial
epithelial cell line (HBE), were purchased from the Insti-
tute of Biochemistry and Cell Biology of the Chinese
Academy of Sciences (Shanghai, China). Cells were cul-
tured in RPMI 1640 (GIBCO-BRL) medium supple-
mented with 10 % fetal bovine serum (10 % FBS), 100
U/ml penicillin, and 100 μg/ml streptomycin (Biyuntian,
China) in humidified air at 37 °C with 5 % CO2.
RNA extraction and qRT-PCR analyses
Total RNA was extracted from cell lines and frozen
tumor specimens using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. The qRT-PCR assays were performed to de-
tect miR-361-3p and SH2B1 expression using the
PrimeScript RT reagent Kit and SYBR Premix Ex Taq
(GeneCopoeia, USA) according to the manufacturer’s
instructions. The relative level of miR-361-3p and
SH2B1 was determined by qRT-PCR using gene specific
primers. U6 or β-actin was used as a normalization
Table 2 SH2B1 expression and clinicopathological features in
non-small cell lung cancer (NSCLC) patients
Variables n SH2B1 expression
+ ++ +++ p value*
Gender
Male 67 16 16 35
Female 24 3 6 15 0.486
Age(years)
> 55 56 14 10 32
≦55 35 5 12 18 0.156
Smoking history
Yes 54 14 11 29
No 37 5 11 21 0.293
Pathological type
Adenocarcinoma 54 15 12 27
Squamous carcinoma 37 4 10 23 0.063
Tumor differentiation
High 22 7 6 9
Middle 58 10 14 34
Low 11 2 2 7 0.518
Tumor location
Right lung 45 11 10 24
Left lung 46 8 12 26 0.696
Tumor size(cm)
> 3 54 8 12 34
≦3 37 11 10 16 0.129
Lymphatic metastasis
Yes 42 0 10 32
No 49 19 12 18 <0.001
TNM classification
I 43 18 10 15
II 22 1 9 12
III + IV 26 0 3 23 <0.001
Abbreviations: TNM tumor-node-metastasis
* χ2test
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Fig. 6 (See legend on next page.)
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control. Levels of miR-361-3p and SH2B1 were normal-
ized to U6 and β-actin, respectively, to yield a 2-ΔΔCt value
for relative expression of each transcript. Experiments
were repeated at least three times. The RT reaction was
carried out under the following conditions: 37 °C for
60 min; 85 °C for 5 min; and then held on 4 °C. After the
RT reaction, the complementary DNA products were di-
luted at 1:5 and 2 μl of the diluted complementary DNA
was used for subsequent qRT-PCR reactions. The qRT-
PCR primers were designed as follows: miR-361-3p,
Forward: 5′-UCCCCCAGGUGUGAUUCUGAUUU-3′,
Reverse: 5′-GCAAATCAGAATCACACCTG-3′. U6, For-
ward: 5′-CTCGCTTCGGCAGCACA-3′, Reverse: 5′-AA





GAPDH, Forward: 5′- TGCACCACCAACTGCTTAG
C-3′, Reverse: 5′-GGCATGGACTGTGGTCATGAG-3′.
The qRT-PCR reaction was conducted at 95 °C for 10 min
and followed by 40 cycles of 95 °C for 10s, 60 °C for 30 s
and 72 °C for 30 s in the ABI 7500 real-time PCR system
(Applied Biosystems, CA, USA). The qRT-PCR results
were analyzed and expressed as relative miRNA expres-
sion of CT (threshold cycle) value, which was then con-
verted to fold changes.
Vector construction and transfection
The hsa-mir-361-precursor sequence was constructed as




GGGAGCTCAACCATACCAG. The sequence was amp-
lified and cloned into the pGC-FU-3FLAG-SV40-EGFP
Vector (GeneChemCo., Shanghai, China) to generate
pGC-FU-miR-361 and the pGC-FU-3FLAG-SV40-EGFP
Vector only as negative control. The hsa-miR-361-3p-in-




TTTTTG. The sequence was amplified and cloned into
the pGCSIL-008 Vector to generate pGCSIL-008-miR-
anti-361-3p. The non-silencing shRNA control sequences
(TTCTCCGAACGTGTCACGT) was cloned into the
pGCSIL-008 Vector as negative control (pGCSIL-008-
RNAi-NC-LV). The SH2B1 expression vector was con-
structed by inserting its CDS sequence into the pEX-2
vector (GeneChem, Shanghai, China). Virus packaging,
production and cell transfection were performed accord-
ing to the manufacture’s protocol. The expression was val-
idated by qRT-PCR. SH2B1-siRNA (si-SH2B1) and non-
specific control siRNA (si-NC) were purchased from Gen-
eChem, Shanghai, China.
Cell proliferation and colony formation assays
Cell proliferation was monitored using CCK8 (Sigma).
LV-miR-361-precursor, LV-negative control transfected
A549 and HTB-182 or anti-miR-361-3p, or pGC FU-
RNAi-NC-LV (Negative control) transfected SPC-A-1
cells (3000 cells/well, 5 wells/group) were allowed to
grow in 96-well plates. Cell proliferation was docu-
mented every 24 h following the manufacturer’s proto-
col. CCK-8 reagent was added to each well at 1.5 h
before the endpoint of incubation. The optical density
(OD) 450 nm values were determined by a microplate
reader. All experiments were repeated at least three
times. For the colony formation assay, LV-miR-361-pre-
cursor, LV-negative control transfected A549 and HTB-
182 cells or LV-anti-miR-361-3p, pGC FU-RNAi-NC-LV
(Negative control) transfected SPC-A-1 cells (100/well)
were allowed to grow in culture dish (8 cm2) and main-
tained in media containing 10 % FBS, replacing the
medium every 4 days. After 14 days, cells were fixed
with methanol and stained with 10 % Giemsa (Solarbio,
Beijing, China). Only positive colonies (diameter > 40
um) in the dishes were counted and compared [40]. All
experiments were performed in triplicate.
In vitro cell migration and invasion assays
For the migration assays, 48 h after transfection, 2 × 104
cells in serum-free media were placed into the upper
chamber of an insert (8 μm pore size, BD). For the inva-
sion assays, 4 × 104 cells in serum-free media were
placed into the upper chamber of an insert coated with
Matrigel (BD, USA). Media containing 10 % FBS were
added to the lower chamber. For migration assays, after
24 h of incubation, and for invasion assays, after 24 h of
incubation, removing the cells remaining on the upper
membrane with cotton wool, whereas the cells that had
migrated or invaded through the membrane were
stained with 10 % Giemsa in methanol, imaged, and
(See figure on previous page.)
Fig. 6 Gain- and loss-of-function study with SH2B1 expression vector and siSH2B1 in cells proliferation in vitro. To investigate whether SH2B1
expression may interfere or mimic the function of miR-361-3p, NSCLC cells were transfected by SH2B1 siRNA or SH2B1 expression vector
to inhibit or restore the SH2B1 expression. CCK8 assay (a), colony formation (b). Data were represented as the mean ± SEM of three
independent experiments. *P < 0.05, **P < 0.01
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Fig. 7 Gain- and loss-of-function study with SH2B1 expression vector and siSH2B1 in migration and invasion in vitro. a migration and invasion
in vitro and wound healing assay in A549; b in HTB-182; c SPC-A-1. The date were put beyond. d Western blot of SH2B1 and its downstream
proteins in stable infected NSCLC cells with SH2B1 expression, siSH2B1 or control vector reintroduced. Data were represented as the mean ± SEM
of three independent experiments. *P < 0.05, **P < 0.01
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counted using an inverted microscope (Canon, Japan).
For wound-healing assay, cells (1 × 106 cells) were
seeded in six-well plates, cultured overnight and trans-
fected with miR-361-precursor, negative control or anti-
miR-361-3p, pGC FU-RNAi-NC-LV (Negative control).
Upon reaching the 95–100 % confluence, the cell layer
was scratched with a 10 μl pipette tip and washed with
culture medium twice and cultured again for up to 24 h
with serum-free medium. Images were captured at dif-
ferent time points (0, 24 h) and the same areas under a
microscope to assess the rate of gap closure. The wound
width of 6 random views was measured, and the healing
width was calculated by wound width at 0 h time point
minus wound width at 24 h time point and normalized
by solvent control [41]. Every experiment was repeated
three times. Bioinformatics methods using bioinformat-
ics software (DIANA TOOL, Targetscan, miRanda) to
predict miR-361-3p potential target gene, combined with
the literature and through the test screening, SH2B1 was
selected as a further object of study.
Luciferase reporter assay
To construct a luciferase reporter vector, SH2B1 3′-
UTR fragment containing putative binding sites for miR-
361-3p was amplified by PCR using the following
primers: h-SH2B1-F: GCGCTCGAGCTATCCAGAAC
CGACCACC h-SH2B1-R:AATGCGGCCGCCACGAT
AGAACCGAGATAA, the PCR product was subcloned
downstream of the luciferase gene in the pLUC Luciferase
vector (Ruibo, Guangzhou,China) and named SH2B1-3′-




miR-361-precursor and HTB-182miR-361-precursor cells grown
in 96-well plate were transfected with 100 ng of
SH2B1-3′UTR-Wt or SH2B1-3′UTR-Mut, using the
Lipofectamie 3000 (Invitrogen, USA). After 72 h of
transfection, luciferase activity was assessed according
to the Dual-Luciferase Reporter Assay protocol (Pro-
mega, Madison, WI). Each experiment was repeated
in triplicates.
Western blotting
Total protein was extracted by lysing cells in RIPA buffer
containing protease inhibitor. Protein samples were
separated by sodium dodecyl sulfate polyacrylamide gel-
electrophoresis (SDS-PAGE) and transferred onto poly-
vinylidenefluoride (PVDF) membranes. After blocking
with 5 % non-fat milk or 3 % BSA in TBS-T, membranes
were incubated with the primary antibody. The following
antibodies were used: SH2B1 (1:1000,Abcam, USA),
JAK2 (1:600, Abcam, USA), p-JAK2 (1:2000, Abcam,
USA), p-Rac1 (1:500, Abcam, USA), Anti-cAMP Protein
Kinase Catalytic subunit (1:60000,Abcam,USA),MMP2
(1:2000,Abcam.,USA), MMP9 (1:1000, Abcam,USA),
GAPDH (1:10000, Abcam, USA) and goat-anti-rabbit
IgG conjugated to horseradish peroxidase (HRP) (1:5000,
Santa Cruz, USA),which was used as the secondary anti-
body. Cells were seeded on 10 cm cell culture plates,
grown to 80 % confluences, and serum starved overnight.
Target signals were quantified by BandScan software
(Bio-Rad, Hercules, CA) and defined as the ratio of
target protein relative to GAPDH.
NSCLC mouse model
Five-week-old BALB/C-nu nude male mice were used
for animal studies, and all animals were maintained in
the specific pathogen-free (SPF) conditions at our insti-
tution. For the in vivo tumor proliferation assay, 3 × 106
A549 cells transfected with LV-miR-361-precursor or
LV-negative control were injected subcutaneously into
the nude mice (5 per group). Tumor growth was moni-
tored by caliper measurement once or twice a week for
at least 4 weeks. Tumor volume was calculated as fol-
lows: V = L× l2 × 0.5, where L and l represent the larger
and the smaller tumor diameters, respectively. The mice
were sacrificed after 4 weeks. For the in vivo tumor
metastasis assay, 2 × 106 A549 cells transfected with LV-
miR-361-precursor or LV-negative control were injected
by the tail vein into the nude mice (5 per group). The
mice were sacrificed after 2 months. At the time of
killing the lung were removed and immediately fixed in
4 % (w/v) paraformaldehyde overnight and treated for
immunohistochemistry.
Immunohistochemical staining
Formalin-fixed, paraffin-embedded tissues were cut into
4-μm sections. Following deparaffinization, sections
were rehydrated and subjected to antigen retrieval by
microwaving in 0.01 M sodium citrate (pH 6) for
10 min. Sections were incubated at 4 °C overnight with
monoclonal antibodies against SH2B1 as mentioned
above. Immunostaining was performed using ChemMate
DAKO EnVision Detection Kit, Peroxidase/DAB,
Rabbit/Mouse (code K5007, DakoCytomation, Glostrup,
Denmark) according to the manufacturer’s instructions
[42]. Subsequently, sections were counterstained with
hematoxylin (Dako) and mounted in dimethyl benzene.
Protein staining was evaluated under a light microscope
at 100 × and 400 ×magnification. Staining intensity was
scored manually by two independent experienced pa-
thologists as 0 = no staining, 1 = weak staining, 2 =mod-
erate staining, and 3 = strong staining. Tumor cells in
five fields were randomly selected and scored based on
the percentage of positively stained cells (0–100 %), as
follows: 0, less than 5 %; 1, 5 to 25 %; 2, 25 to 50 %; or 3,
more than 50 %. The final ICH score was then
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calculated by adding the two above scores, and scores of
0–2 were considered as low expressions while scores of
3–6 were defined as high expressions [43, 44].
Statistical analysis
The relationship between miR-361-3p expression and
clinicopathologic parameters was analyzed using the
Pearson χ2 test. Spearman’s correlation analysis was used
to determine correlation between miR-361-3p and SH2B1
expression. The differences between groups were analyzed
using Student t test when there were only two groups, or
assessed by one-way ANOVA when there were more than
two groups. All statistical analyses were performed using
the SPSS software (version 19.0, Chicago, IL). A two-tailed
value of P < 0.05 was considered statistically significant.
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